API Maker NuSil Warned for Quality, Contamination Concerns
NuSil Technology, a California-based maker of active pharmaceutical ingredients (APIs) and industrial silicone products, has been warned for specification testing shortfalls and microbial contamination concerns related to its simethicone emulsion USP.
FDA investigators found out-of-specification (OOS) reports lacking key data for a lot of simethicone emulsion USP that had been twice-tested for microbial contamination, the March 22 warning letter posted Tuesday states. The letter comes after an April 18 through May 4, 2011, inspection of the company’s Bakersfield, Calif., plant.
The OOS report for the lot, which was subsequently released, failed to justify the invalidation of the original results and lacked root cause determination, according to the letter. NuSil “relied solely on the acceptable retest results to release the lot,” the FDA said.
No FDA-regulated manufacturers are inspected more rigorously than API firms. These companies’ specialized operations, and their crucial role in the drug-making process, make them frequent FDA inspection targets. There’s a lot that can be learned from the Form 483s resulting from such inspections — for both the API manufacturers and for the drug and biologics makers that do business with them.
Imagine having access to recent FDA inspection reports on API manufacturers — especially if they’re your competitors — whenever you need them.
A Form 483 is the FDA’s most detailed public record of inspection findings, but a Form 483 is also invaluable “inside intelligence” when you want to know what FDA inspectors have found in other companies and what they’ll look for on inspection day in your own plant.
Whether you work in regulatory affairs, quality control or on the factory floor, you’ll find real-life details about how the FDA does its job when you order this book today.
Come for this valuable opportunity to hear FDA officials discuss regulatory plans and objectives — and ask questions you need answered; learn from device industry experts, consultants and other experts with actionable tips and strategies you can take straight back to the office; and network with other professionals who understand your challenges; share war stories and insights over a drink. Register Today.Read More
The FDA's new enforcement plan makes one thing clear: Developing a successful CAPA program has never been more important. But creating an FDA-proof CAPA isn’t easy. If only you could pick the brain of someone who is coping successfully with CAPA — the best and the brightest, an industry leader who has devised programs, procedures and solutions that have put companies out in front with the FDA. Well, you can. Register today.Read More
The FDA’s cadre of freshly trained inspectors — many of whom come directly from industry — and increased focus on specialized inspections are making it harder than ever to predict the outcome of your next FDA inspection. Unless, of course, you have Surviving an FDA Inspection at your fingertips. If you could spend less than $400 to get your drug manufacturing facility fully prepared to face a tough inspection by the FDA, would you even hesitate? ... Of course not!